KFRX06 / KeifeRx, Amneal - LARVOL DELTA

KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease (Businesswire) - "Under the agreement, KeifeRx will conduct a research program intended to generate key pre-IND outputs to support Amneal’s evaluation of KFRX06 and inform potential next-stage development. Financial terms of the agreement were not disclosed."

Licensing / partnership • Parkinson's Disease